Bionik Laboratories Corp.
BNKL · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -12.9% | 18.3% | 100.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 50.7% | 47% | 61.2% | 69% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -255.9% | -178.4% | -226.2% | -563.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -282.5% | -192.9% | -236% | -574.5% |
| EPS Diluted | -0.2 | -0.16 | -0.17 | -0.2 |
| % Growth | -25% | 5.9% | 15% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |